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Graphical abstract
Highlights
• Levels of circulating DNA, IL6, and TBARS are higher
in patients with ACLF than in patients with AD
• Circulating DNA, IL6, and TBARS are higher in
patients with organ failure and those who died
• Circulating DNA, IL6, and TBARS are not correlated
with markers of activation of coagulation
• The neutrophil extracellular trap marker MPO-DNA
was not related to coagulation or outcome
• DNA- or NET-related coagulation does not appear to
drive ACLF progression
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Lay summary
Acute-on-chronic liver failure is a devastating syn-
drome that can follow acute decompensation of
chronic liver disease. Herein, we demonstrate that
these patients accumulate DNA released from dying
cells in their blood, and that the quantity of this DNA
is related to the outcome of disease. We also show that
outcome of disease is not related to recently described
neutrophil extracellular traps, which have been shown
in animal models to play vital roles in the progression
of liver diseases.
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Background & Aims: Acute-on-chronic liver failure (ACLF) is a recently (re)defined syndrome of acute decompensation of cir-
rhosis that presents with extrahepatic organ failure(s) and poor outcome. Given the prominent role of inflammation and acti-
vation of coagulation in ACLF, we hypothesized that ACLF might be characterized by the generation of neutrophil extracellular
traps (NETs), that could drive both activation of coagulation and progression of organ failure.
Methods: Wemeasured markers of circulating DNA, activation of coagulation, inflammation, and oxidative stress in 52 patients
with acute decompensation (AD) of cirrhosis and 57patientswithACLF on admission, and compared levelswith 40healthy controls.
Results: All analytes were higher in patients compared to controls. Plasma levels of cell-free DNA, but not of the specific NETmar-
ker myeloperoxidase-DNA complexes were higher in patients with ACLF compared to AD cirrhosis. In addition, TAT complexes
(coagulation), IL-6 (inflammation), andTBARS (oxidative stress)werehigher inACLF compared toAD.Markers for activation of coa-
gulation were not associated with circulating DNA, IL-6, or TBARS. In contrast, levels of circulating DNA, IL-6, and TBARS were
higher in patients with more severe disease, higher in patients with organ failure, and higher in patients that died within 30 days
of admission. Importantly, myeloperoxidase-DNA levels did not differ between patients with complications and poor outcome.
Conclusions: Collectively, we show that cell-freeDNA, inflammation, and oxidative stress are associatedwith outcomes inAD and
ACLF, but notwith activation of coagulation. Our data argue against a role of NETs in activation of coagulation and in progression of
organ failure in patients with AD and ACLF.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Acute-on-chronic liver failure (ACLF) is a recently (re)defined syn-
drome characterized by acute decompensation (AD) of cirrhosis
(development of ascites, hemorrhage, encephalopathy and/or bac-
terial infection), organ failure (liver, kidney, brain, coagulation,
respiration, circulation), and high short-term mortality.1–3 Patients
with ACLF exhibit a very dynamic disease course. Patients may
improve (50%) or worsen (20%) within a short period of time, and
prognosis depends on the early clinical course.4 The pathogenesis
underlying the ACLF syndrome have not been well elucidated,
but a systemic inflammatory response appears to play a centralKeywords: cirrhosis; liver; acute-on-chronic liver disease; neutrophil extracellular trap;
coagulation; sepsis; mortality; inflammation; oxidative stress.
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‡ Joint senior authorsrole. It not known preciselywhich factors induce this inflammatory
response. Sepsis, acute alcoholic hepatitis, and reactivation
of chronic viral hepatitis are precipitating factors for ACLF in
some patients, but up to 40–50% of cases have no identifiable
trigger.1
Patients with AD and ACLF have complex changes in their
hemostatic system, with both hypo- and hypercoagulable fea-
tures.5,6 Indeed, both bleeding and thrombotic complications are
common in these patients7, although the incidence and severity
of these hemostatic complications have not been systematically
documented in large series. Local or systemic activation of hemos-
tasis may result in macrovascular thrombotic complications such
as deep vein thrombosis or portal vein thrombosis. In addition,
microvascular thrombotic events may occur and precipitate or
worsen organ failure, a phenomenon that has been well estab-
lished in the context of sepsis without underlying liver disease8
and in patients with disseminated intravascular coagulation.9
Since activation of the hemostatic system is accompanied by
inflammatory responses and vice versa,10,11 a role of the complex
reciprocal interactions between hemostasis and inflammation in
macro- and microvascular thrombotic complications is likely.
Research ArticleNeutrophil extracellular traps (NETs) have recently been
described as a link between inflammation and coagulation.12,13
NETs are a web-like structure composed of neutrophil DNA com-
plexed to various neutrophil-derived proteins and are generated
following activation of neutrophils by various stimuli. NETs were
originally described as a mechanism to enable neutrophils to
entrap and kill pathogens.14 Subsequently, it was demonstrated
that NETs can be generated in the absence of pathogens, and
NETs are now implicated as drivers of a variety of non-infectious
diseases including diabetes, atherosclerosis, cancer, and trauma.15
In addition, NETs have been shown to be potent activators of
hemostasis, and have been implicated in thrombotic disease.16–18
We have recently reported generation of NETs during
liver transplantation in humans.19 Although there is clear activa-
tion of coagulation during liver transplantation, we found no
evidence of a role for NETs in driving this process. Rather, the
release of cell-free DNA, likely from hepatocytes damaged by
ischemia-reperfusion injury, appeared to drive activation of
coagulation. However, NET formation was assessed in systemic
circulation, and it may be that NETs do drive activation of coagu-
lation locally.
Given the role of systemic inflammation in ACLF,4 the estab-
lished role of NETs in infection and sepsis,20 the role of NETs in var-
ious types of liver injury,21 and the hypercoagulable features of the
hemostatic system in ACLF,5 we hypothesized that NETs are gener-
ated in AD, but particularly in ACLF, and that NETs drive activation
of coagulation with subsequent worsening of organ failure.
Materials and methods
Patients
Between February 2018 and September 2018, adult patients with
acutely decompensated cirrhosis (AD, n = 52) or acute-on-chronic
liver failure (ACLF, n = 57) consecutively admitted to King's
College Hospital London (United Kingdom) and Hospital
Clinic Barcelona (Spain) who gave written informed consent
were included in this study. The NRES Committee London-
Westminster (12/LO/1417) and the medical ethical committee of
Hospital Clinic Barcelona (2017/0948) approved the study protocol
which was in accordance with the Helsinki Declaration of 1975.
Informed consent was obtained from participants or from personal
consultees when the patients were incapacitated and unable to
provide informed consent. Exclusion criteria for this study were
acute liver failure, known congenital coagulation disorders, the
use of anticoagulants or platelet function inhibitors, pregnancy, ser-
ological evidence of the HIV, or evidence of disseminated malig-
nancy. Cirrhosis was defined by the presence of 2 or more of: i)
histological evidence of cirrhosis on liver biopsy, ii) laboratory
abnormalities consistent with cirrhosis or iii) radiological findings
consistent with cirrhosis and portal hypertension. AD of chronic
liver disease and ACLF were defined and graded according to num-
ber of organ failures in concordance with criteria reported in the
CANONIC study,1 see http://www.efclif.com/scientific-activity/
score-calculators for online score calculator. Patients were
followed-up until 30 days after discharge, death or transplant,
whatever happened first. Healthy controls aged >18 years (n = 40)
were enrolled to establish reference values for the various
laboratory tests performed, and excluded those with a personal
history of thrombotic or liver-related diseases, medical condi-
tions known to be associated with hemostatic alterations, or
current use of anticoagulants, platelet function inhibitors, or
oral contraceptives.JHEP Reports 2019Data collection
We collected data on patient demographics, comorbidities, bio-
chemistry and illness severity scores. The severity of liver dis-
ease was evaluated with sequential organ failure assessment
(SOFA), Chronic Liver Failure Consortium (CLIF)-AD, CLIF-ACLF,
model of end-stage liver disease (MELD), and Child-Pugh scores.
Sepsis syndrome was defined according to the SEPSIS-3
guidelines.
Blood samples
Blood samples were collected in sodium citrate-containing
vacutainer tubes (0.129 M) from an arterial line, central venous
catheter, or by standard peripheral venous phlebotomy within
the first 2 days of admission or after the development of ACLF.
Samples were obtained prior to the administration of blood
products, anticoagulants, or platelet function inhibitors.
Within 2 h after the blood draw, the sample was centrifuged
at 2.000 g and 10.000 g respectively for 10 min at ambient
temperature. Plasma was stored at -80°C until it was used for
analyses.
Assessment of cell-free DNA, coagulation activation, inflam-
matory markers and oxidative stress
The concentration of cell-free DNA (cfDNA) was measured using
the Quant-iT PicoGreen double strand DNA assay kit (Fisher
Scientific, Landsmeer, the Netherlands). In short, 10 μl of plasma
was added to 90 μl of Tris-EDTA (TE) buffer (10mM Tris-HCl,
1mM EDTA, pH 7.5) in a 96-well microtiter plate. Next, 100 μl of
PicoGreen solution (diluted 1:200 in TE buffer) was added to
the wells. After 10minutes of incubation in the dark at room tem-
perature, fluorescence was measured at 480 nm excitation and
520 nm emission using a Victor3 (PerkinElmer, Groningen, the
Netherlands) spectrophotometer. The concentration of nucleo-
somes in the plasma samples was determined using the cell
death detection ELISA (Sigma-Aldrich, Zwijndrecht, The Nether-
lands). The test was performed according to the manufacturer’s
instructions. Complexes of myeloperoxidase (MPO) and DNA – a
selective marker for neutrophil extracellular traps in plasma –
were quantified by ELISA as previously described22 using a com-
mercially available monoclonal antibody (clone 4A4) to MPO
(Sanbio, Uden, the Netherlands) and the detection antibody
derived from the cell death detection ELISA (Sigma-Aldrich,
Zwijndrecht, The Netherlands). To assess activation of coagula-
tion the concentration of thrombin/antithrombin complex
(TAT), which is an established marker for in vivo thrombin gen-
eration, was determined. Quantification of TAT was done with
the use of Enzygnost TAT micro ELISA kit (Siemens Healthcare
Diagnostics, the Hague, the Netherlands), according to the manu-
facturers’ protocol. Levels of D-dimers were measured on the ACL
300 top using the HemosIL D-Dimer HS500 assay which was
obtained from Werfen (Breda, The Netherlands). Interleukin 6
(IL-6) levels were determined using a commercially available
ELISA from R&D Systems (Minneapolis, MN, USA). Thiobarbituric
acid-reactive substances (TBARS) were measured as a marker for
oxidative stress as previously described.23
Statistical analyses
Statistical analyses were performed using SPSS statistics, version
23 (IBM inc., Chicago Illinois, USA) and GraphPad Prism (San
Diego, USA). Data were presented as means with standard devia-
tion or medians and interquartile ranges (IQRs) for continuous
variables as appropriate, and as percentages for categoricalvol. 1 | 179–187 180
variables. Means of 2 groups were compared by Mann-Whitney
U test as all analyteswere not normally distributed.Multiple groups
were compared Kruskal-Wallis H test (with Dunn’s post hoc test).
Pearson’s correlation coefficient was used to assess the correlation
between variables. A p value <0.05 was considered significant.
Results
Patient characteristics
We have studied levels of cfDNA, markers for activation of co-
agulation, markers for oxidative stress and inflammatory mar-
kers in the plasma of 52 adult patients with AD cirrhosis and 57
adult patients with ACLF. We compared these levels with
plasma concentrations in 40 healthy controls. Patient demo-
graphics, clinical and laboratory data are presented in Table 1.
Healthy controls were younger than patients (35 [28-43] years,
and 45% were male). Among patients with ACLF, 27 (47%) had
ACLF grade 1 (23 of those had renal failure only), 13 (23%) ACLFTable 1. Demographic and laboratory data of the study population.
Age, years
Male
Etiology
Alcohol
Viral
NASH
Biliary
Other
SOFA score
CLIF–SOFA score
MELD
Child-Pugh
Haemoglobin, g/dl
mmol/L
Leucocytes, x109/L
Neutrophils, x109/L
Na, mmol/L
Urea, mg/dl
mmol/L
Creatinine, mg/dl 0
μmol/L
Bilirubin, mg/dl
μmol/L
Gamma glutamyltransferase, IU/L
Alkaline phosphatase, IU/L
Aspartate aminotransferase, IU/L
Albumin, g/L
Platelets, x109
Fibrinogen, g/L
INR
APTT, seconds
APTT, activated partial thromboplastin time; CLIF, Chronic Liver Failure Consortium; INR
alcoholic steatohepatitis; SOFA, sequential organ failure assessment.
JHEP Reports 2019grade 2 and 17 (30%) ACLF grade 3, at inclusion. Infectionwas pre-
sent in 7 (14%) and 26 (46%) patients with AD and ACLF, respec-
tively, at inclusion.
DNA levels in systemic circulation in patients with AD
cirrhosis and ACLF
Wequantified plasma levels of cfDNA, nucleosomes, andMPO-DNA
complexes in samples from patients with AD cirrhosis and ACLF
(Fig. 1). Plasma levels of cfDNA, nucleosomes, and MPO-DNA com-
plexes were significantly higher in the AD and ACLF cohorts, com-
pared to levels in healthy controls. Additionally, levels of cfDNA
and nucleosomes were significantly higher in patients with ACLF
compared to levels in patients with AD cirrhosis. MPO-DNA levels
were not significantly different between the AD and ACLF cohorts.
cfDNA and nucleosome levels were higher in patients with sepsis
compared to patients without sepsis, whereas MPO-DNA levels
were similar in patients with and without sepsis. Levels of cfDNA
and nucleosomes remained significantly higher in patients withAD
n = 52
ACLF
n = 57
58 (50–67) 59 (49–66)
29 40
32 33
0 11
10 6
3 2
7 5
4 (3–6) 8 (6–11)
60 (47–108) 87 (74–97)
15 (11–21) 27 (23–35)
9 (7–10) 10 (8–12)
8.6 (8.0–11.0) 8.5 (7.7–9.9)
5.0 (5.3–6.8) 5.3 (4.8–6.1)
5.5 (3.6–6.5) 8.2 (3.6–13.7)
2.9 (2.1–3.9) 3.6 (1.7–9.1)
136 (132–139) 135 (132–141)
14 (8–22) 22 (11–25)
5 (3–8) 8 (4–9)
.83 (0.61–1.23) 2.39 (1.52–3.19)
73 (54–109) 211 (134–282)
2.3 (1.6–5.9) 5.8 (2.3–22.3)
39 (28–101) 100 (40–381)
77 (43–145) 70 (42–1589
120 (82–181) 116 (80–142)
62 (44–100) 65 (40–108)
29 (26–33) 29 (24–33)
88 (62–127) 70 (38–107)
2.2 (1.4–2.9) 1.8 (1.1–2.5)
1.4 (1.3–1.8) 1.7 (1.4–2.6)
36 (30–43) 41 (33–56)
, international normalized ratio; MELD, model of end-stage liver disease; NASH, non-
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Fig. 1. Elevated levels of circulating DNA in acutely ill patients with cirrhosis. Plasma levels of (A) cfDNA, (B) nucleosomes, and (C) complexes of MPO and DNA
(MPO-DNA), were determined in patients with AD, ACLF, and healthy controls. Plasma levels of (D) cfDNA, (E) nucleosomes, and (F) complexes of MPO and DNA
(MPO-DNA), were determined in patients with and without sepsis. Horizontal lines indicate medians. A, B, C: Kruskal-Wallis H test with Dunn’s post hoc test; D,
E, F: Mann-Whitney U test. AD, acute decompensation; ACLF, acute-on-chronic liver failure; cfDNA, cell-free DNA; MPO, myeloperoxidase.
Research ArticleACLF compared to those with AD when analyses were repeated
without the patients with sepsis (median cfDNA 0.37 μg/ml
[0.30–0.49] in AD vs. 0.58 [0.40–0.78] in ACLF p <0.001; nucleo-
somes 96 mU [52–206] in AD vs. 211 [49–400] in ACLF p = 0.044).
In contrast, MPO-DNA levels were similar between AD and ACLF
when patients with sepsis were excluded from the analysis (0.86
AU [0.41–1.35] in AD vs. 0.99 [0.62–1.19] in ACLF). In a subset of
32 patientswith ACLF, we took a second sample 72 h after inclusion
in the study. We observed a small, although statistically significant,
change in cfDNA levels over the 72 h (0.67 μg/ml [0.55–0.82] at
baseline vs. 0.58 [0.46–0.84] at 72 h, p <0.01), consistent with little
change in other laboratory parameters over this short period of
time (C-reactive protein 2.8 mg/L (1.4–6.3) at baseline vs. 3
(1.4–6.0) at 72 h, not significant; lactate 18mmol/L (13–27) at base-
line vs. 15 (13–24) at 72 h, p = 0.03, leukocyte count 5.2 x 109/L
(2.6–9.6) at baseline vs. 5.1 (3.4–9.3) at 72 h, not significant).Fig. 2. Activation of coagulation in acutely ill patients with cirrhosis. (A)
Plasma levels of TAT and (B) D-dimers, were determined in patients with AD,
ACLF, and healthy controls. Horizontal lines indicate medians. Comparisons by
Kruskal-Wallis H test with Dunn’s post hoc test. AD, acute decompensation;
ACLF, acute-on-chronic liver failure; TAT, thrombin-antithrombin complexes.
JHEP Reports 2019Activation of coagulation in patients with AD and ACLF
Activation of coagulation was assessed by plasma levels of TAT
complexes and D-dimers (Fig. 2). Substantially and significantly
increased levels of TAT complexes and D-dimers were observed
in patients with AD and ACLF, compared to healthy controls.
Furthermore, TAT levels were significantly higher in patients
with ACLF compared to patients with AD.
Systemic inflammation and oxidative stress in patients with
AD and ACLF
Systemic inflammation and oxidative stress were assessed by
plasma levels of IL-6 and TBARS, respectively (Fig. 3). Both IL-6
and plasma TBARS were higher in patients compared to controls.
In addition, IL-6 was higher in patients with ACLF compared to
patients with AD, and within the ACLF cohort, levels of TBARS
were higher in patients with ACLF grades 2 and 3 compared toFig. 3. Inflammation and oxidative stress in acutely ill patients with
cirrhosis. Plasma levels of (A) IL-6, and (B) TBARS, were determined in
patients with AD, ACLF, and healthy controls. Horizontal lines indicate
medians. Comparisons by Kruskal-Wallis H test with Dunn’s post hoc test. AD,
acute decompensation; ACLF, acute-on-chronic liver failure; IL-6, interleukin
6; TBARS, thiobarbituric acid-reactive substances.
vol. 1 | 179–187 182
Table 2. Correlation between markers for activation of coagulation and circulating DNA, MPO-DNA complexes, nucleosomes, IL-6, and TBARS.
cfDNA MPO-DNA Nucleosomes IL-6 TBARS
TAT r2= 0.006 r2= 0.003 r2= 0.001 r2 = 0.0003 r2= 0.0002
p = 0.401 p = 0.482 p = 0.663 p = 0.857 p = 0.865
D–dimer r2= 0.003 r2= 0.015 r2= 0.047 r2 = 0.002 r2= 0.001
p = 0.561 p = 0.199 p = 0.023 p = 0.582 p = 0.665
Linear correlation coefficients (Pearson’s) with corresponding p values between the indicated analytes are presented for all patients combined. cfDNA, cell-free DNA; IL-6, inter-
leukin 6; MPO, myeloperoxidase; TAT, thrombin-antithrombin complexes; TBARS, thiobarbituric acid-reactive substances.patientswith grade 1 ACLF (13.0 μM (8.1–15. 8) vs. 3.9 μM(2.8–5.1),
p <0.001).
Lack of association between activation of coagulation and
circulating DNA, inflammation, and oxidative stress
Given the established roles of circulating DNA, inflammation, and
oxidative stress in activation of coagulation, we assessed linear cor-
relations between TAT complexes and D-dimer levels with levels of
circulating DNA, IL-6, and TBARS (Table 2). In all patients combined,
we did not find any linear relations between TAT or D-dimer levels
and levels of circulating DNA, IL-6, or TBARS. Also, when these
analyses were repeated in patients with AD and ACLF separately,
no linear relations were detected (data not shown).
Circulating DNA, inflammation, and oxidative stress in
relation to organ failure
Westratified patients according to overall clinical scores (Table 3).
In patients with a SOFA score below the median, plasma levels of
cfDNA, IL-6, TBARS, and D-dimer were significantly lower com-
pared to patients with a SOFA score above the median. cfDNA,
nucleosome, Il6, TBARS and D-dimer levels were significantly
lower in patients with CLIF-AD scores below themedian, whereas
cfDNA and TBARS were lower in patients with CLIF-ACLF below
the median. cfDNA, IL-6 levels, TBARS, and D-dimers were lower
in patients with Child-Pugh scores below the median.
We subsequently assessed plasma levels of these analytes per
organ failure. Levels of cfDNA, nucleosomes, Il6, and TBARS were
higher in patients that had failure of any organ system (although
not all comparisons reached statistical significance), whereas D-
dimer levels were higher with any organ failure except liver
failure. In contrast, MPO-DNA levels were only clearly increased
in patients with renal failure.
Association of cfDNA, plasma levels of IL-6 and TBARS with
short-term mortality
Seventeen (15%) patients (15 ACLF and 2 AD) died within 30 days
after hospital admission. Baseline levels of cfDNA, nucleosome, D-
dimer, IL-6 and TBARSwere higher in patients that diedwithin 30
days, compared to 30-day survivors (Table 4), although the differ-
ence did not reach statistical significance for nucleosome levels
(p = 0.177). Baseline levels of other analytes were not different
between survivors and non-survivors.
Discussion
In this study, we found elevated plasma levels of circulating DNA,
and elevated plasma levels of markers for activation of coagula-
tion, systemic inflammation and oxidative stress in acutely ill
patients with cirrhosis. All analytes were higher in patients with
ACLF than in patients with AD with the notable exception of
levels of MPO-DNA complexes, which is an established marker
for NETs. We found no evidence for a role of circulating DNA,
inflammatory stress, or oxidative stress in activation ofJHEP Reports 2019coagulation in these patients. cfDNA, Il6, and TBARS much better
discriminated between patients with organ failure than MPO-
DNA levels. Finally, we found levels of circulating DNA, and mar-
kers for inflammatory and oxidative stress to be substantially
higher in those patients with poor outcome.
Experimental studies have established that NETs are important
contributors to micro- and macrovascular thrombus formation as
infusion of DNAse,16 which dismantles NETs, or a genetic defect in
NET formation, by PAD4 deficiency for example,24 reduces throm-
bus formation. In addition, NETs have been detected in human
thrombi,17,25 and plasma levels of circulating DNA are elevated in
patients with thrombotic disease.26 However, whether NETs, com-
ponents of NETs, or free circulating DNA indeed contribute to acti-
vation of hemostasis in humans or whether elevated levels of
these components are simply a consequence of the thrombotic
event has not been established. Importantly, despite convincing
evidence for a role of NETs in thrombotic events in experimental
models, it remains controversial whether NETs27 or cfDNA28 can
activate coagulation to a relevant extent in the human setting.
A previous study from our group showed that plasma levels of
cfDNA, but not of MPO-DNA as a marker for NET formation, were
associated with activation of coagulation in patients undergoing
liver transplantation.19 As we demonstrated NET formation
within the liver, we hypothesized that NETs might contribute to
activation of coagulation locally. Our present data extended
these studies with the notion that a systemic inflammatory
response with an increased neutrophil count is central in the
ACLF syndrome.29,30 However, although we confirm an elevated
inflammatory response in patients with ACLF, as evidenced by
increased IL-6 levels, we did not detect increased NETosis, as
MPO-DNA levels were similar between patients with AD and
ACLF. It may be that the concept of immuneparalysis31,32 (i.e., leu-
kocyte dysfunction in cirrhosis) results in declining capacity to
form NETs with increasing disease severity, and interestingly
the patients that became septic had numerically lower levels of
MPO-DNA complexes than patients without sepsis. Alternatively,
NETosis might occur locally, without massive release of MPO-
DNA complexes into systemic circulation, and the assessment of
local NETosis with potential local thrombotic consequences,
although of definitive interest in these patients, is complex as it
would require tissue biopsies at the time of severe disease.
Our present data suggest substantial activation of coagulation
in acutely ill patients with cirrhosis, with an exaggerated
response in ACLF compared to AD. Although these results are in
line with our previous finding of enhanced thrombin generating
capacity in patients with AD and ACLF,512 it is important to stress
that elevated levels of D-dimer and TAT may indeed reflect
enhanced coagulation activation, but may also, in part, be
explained by a decreased capacity of the diseased liver to clear
these markers.33 We did not find evidence for a role of circulating
DNA in activation of coagulation in these patients, and future
studies should assess whether the enhanced activation ofvol. 1 | 179–187 183
Table 3. Levels of circulating DNA, MPO-DNA complexes, nucleosomes, IL-6, and TBARS, TAT, and D-dimers.
SOFA (median value 6)
Low (≤6), n = 61 High (>6), n = 48 p
cfDNA, μg/ml 0.46 (0.35–0.55) 0.72 (0.47–0.95) <0.001
MPO-DNA, AU 0.81 (0.41–1.11) 0.94 (0.63–1.30) n.s.
Nucleosomes, mU 125 (54– 252) 193 (71– 382) n.s.
IL-6, ng/ml 22 (10– 54) 50 (25– 109) <0.001
TBARS, μM 4.5 (3.3– 6.5) 8.9 (4.9–15.2) <0.001
TAT, μg/ml 6.4 (4.0–15.5) 9.5 (5.9– 18.7) n.s.
D-dimers, ng/ml 2,391 (1,085–5,501) 6,301 (2,220–12,056) <0.001
CLIF-AD (median value 51)
Low (≤ 51), n = 25 High (>51), n = 27 p
cfDNA, μg/ml 0.36 (0.29–0.42) 0.48 (0.37–0.68) <0.01
MPO-DNA, AU 0.69 (0.20–1.23) 0.92 (0.42–1.31) n.s.
Nucleosomes, mU 53 (39–126) 118 (71–255) <0.01
IL-6, ng/ml 11 (4–16) 39 (22–90) <0.001
TBARS, μM 4.1 (3.3–4.9) 5.5 (3.8– 11.2) 0.02
TAT, μg/ml 5.0 (3.2–6.9) 8.5 (3.9–15.4) n.s.
D-dimers, ng/ml 1,588 (650–2,317) 4,751 (2,391–7,182) <0.001
CLIF-ACLF (median value 53)
Low (≤ 53), n = 29 High (>87), n = 28 p
cfDNA, μg/ml 0.49 (0.37–0.63) 0.75 (0.65–1.06) <0.001
MPO-DNA, AU 0.94 (0.66–1.16) 0.83 (0.58–1.15) n.s.
Nucleosomes, mU 216 (50–382) 211 (154–485) n.s.
IL-6, ng/ml 48 (20– 100) 77 (34–175) n.s.
TBARS, μM 4.7 (3.0– 7.0) 8.8 (4.9–15.1) <0.001
TAT, μg/ml 10.6 (6.5–19.3) 10.1 (5.3–20.5 n.s.
D-dimers, ng/ml 5,327 (1,603–7,137) 6,076 (2,853–8,363) n.s.
Child-Pugh (median value 9)
Low (≤ 9), n = 55 High (>9), n = 54 p
cfDNA, μg/ml 0.45 (0.35–0.56) 0.67 (0.47–0.89) <0.001
MPO-DNA, AU 0.86 (0.53–1.02) 0.98 (0.59–1.39) n.s.
Nucleosomes, mU 102 (53–250) 193 (74–377) n.s.
IL-6, ng/ml 22 (11– 62) 47 (18– 92) 0.04
TBARS, μM 3.9 (3.1– 4.8) 10.4 (6.0– 15.4) <0.001
TAT, μg/ml 7.0 (4.1–14.4) 9.8 (5.0–17.2) n.s.
D-dimers, ng/ml 2,215 (1,013–4,751) 6,268 (3,310–7,450) <0.001
Liver failure (bilirubin >205 μmol/L)
No, n = 80 Yes, n = 29 p
cfDNA, μg/ml 0.46 (0.35–0.56) 0.86 (0.66–1.24) <0.001
MPO-DNA, AU 0.88 (0.52–1.1) 0.86 (0.64– 1.25) n.s.
Nucleosomes, mU 125 (53– 254) 211 (89– 485) 0.01
IL-6, ng/ml 25 (11– 74) 48 (22–101) n.s.
TBARS, μM 4.5 (3.6– 6.4) 15.3 (9.8– 16.8) <0.001
TAT, μg/ml 8.9 (4.9–18.7) 11.1 (4.2–15.3) n.s.
D-dimers, ng/ml 4,031 (1,412–7,122) 4,427 (2,962–6,991) n.s.
Renal failure (creatinine >176 μmol/L)
No, n = 65 Yes, n = 44 p
cfDNA, μg/ml 0.45 (0.35–0.54) 0.81 (0.67–1.15) <0.03
MPO-DNA, AU 0.74 (0.41–1.14) 0.99 (0.73–1.18) 0.03
Nucleosomes, mU 109 (57–221) 211 (57–418) n.s.
IL-6, ng/ml 23 (10–68) 48 (22– 101) <0.01
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Table 3 (continued)
TBARS, μM 4.9 (3.8–10.4) 6.0 (3.8– 12.1) n.s.
TAT, μg/ml 6.5 (3.8–15.3) 9.8 (5.5–19.7) n.s.
D-dimers, ng/ml 3,219 (1,351–6,887) 5,304 (1,699–7,107) 0.03
Coagulation failure (INR >2.5)
No, n = 90 Yes, n = 19 p
cfDNA, μg/ml 0.47 (0.35 0.62) 0.81 (0.66–1.13) <0.001
MPO-DNA, AU 0.86 (0.52–1.18) 0.64 (0.99 1.18) n.s.
Nucleosomes, mU 127 (54–300) 191 (93–352) n.s.
IL-6, ng/ml 28.6 (12.8–84.2) 48.4 (14.2– 109.5) n.s.
TBARS, μM 4.6 (3.6–7.9) 11.7 (6.9– 16.1) <0.001
TAT, μg/ml 8.4 (4.1–18.0) 9.6 (6.0–12.7) n.s.
D-dimers, ng/ml 2,923 (1,334–6,995) 6,076 (3,859–7,122) 0.04
Hemodynamic failure (MAP 80 mmHg with vasoactive support)
No, n = 88 Yes, n = 21 p
cfDNA, μg/ml 0.48 (0.36–0.65) 0.80 (0.65–1.07) <0.001
MPO-DNA, AU 0.90 (0.52–1.21) 0.83 (0.62–1.06) n.s.
Nucleosomes, mU 121 (55–289) 204 (130– 414) n.s.
IL-6, ng/ml 25.3 (11.1–66.6) 81.3 (41.7–111.1) <0.01
TBARS, μM 4.9 (3.8–9.2) 9.5 (6.0–16.1) 0.02
TAT, μg/ml 7.6 (4.1–15.2) 10.3 (6.0–20.6) n.s.
D-dimers, ng/ml 3,028 (1,326–6,594) 6,076 (3,172–1,1761) 0.01
Respiratory failure (PaO2/FiO2 <200)
No, n = 98 Yes, n = 11 p
cfDNA, μg/ml 0.48 (0.36–0. 68) 1.02 (0.80–1.40) <0.001
MPO-DNA, AU 0.90 (0.52–1.19) 0.68 (0.63–0.99) n.s.
Nucleosomes, mU 133 (55–297) 196 (90–728) n.s.
IL-6, ng/ml 27.2 (11.4–69.6) 109.5 (77.1–603.9) <0.001
TBARS, μM 4.9 (3.7–9.5) 15.1 (6.9–18.9) <0.01
TAT, μg/ml 8.2 (4.1–15.4) 10.1 (8.7–19.9) n.s.
D-dimers, ng/ml 3,380 (1,397–6,995) 6,293 (4,427–9,505) 0.03
Neurologic failure (encephalopathy moderate-severe)
No, n = 76 Yes, n = 33 p
cfDNA, μg/ml 0.47 (0.35–0.64) 0.72 (0.49–0.99) <0.001
MPO-DNA, AU 0.94 (0.58–1.32) 0.68 (0.43–1.00) n.s.
Nucleosomes, mU 121 (57–220) 255 (70–506) 0.02
IL-6, ng/ml 26.6 (12.0–76.5) 47.4 (18. 9– 109.5) n.s.
TBARS, μM 4.6 (3.5–7.3) 9.3 (5.3–15.5) <0.001
TAT, μg/ml 6.4 (4.0–14.3) 10.3 (7.1–18.3) <0.01
D-dimers, ng/ml 2,624 (1,345–6,169) 6,207 (3,700–8,518) <0.01
Stratified by low and high SOFA, CLIF-AD, CLIF-ACLF, and Child-Pugh scores and by the presence / absence of liver, renal, coagulation, hemodynamic, respiratory and neurological
failure. Median and interquartile ranges are shown with corresponding p values. Comparisons by Kruskal-Wallis H test with Dunn’s post hoc test.
AD, acute decompensation; ACLF, acute-on-chronic liver failure; cfDNA, cell-free DNA; CLIF OF, Chronic Liver Failure Consortium organ failure score; IL-6, interleukin 6;
MPO, myeloperoxidase; MAP, mean arterial pressure; SOFA, sequential organ failure assessment; TAT, thrombin-antithrombin complexes; TBARS, thiobarbituric acid-
reactive substances. Comparisons by Mann Whitney U test.coagulation is real (and not an artifact related to defective clear-
ance), and if so, what the trigger of coagulation activation in
these patients might be. Animal experiments have suggested a
key role for activation of tissue factor on ‘stressed’ hepatic cells
in activation of coagulation.34 If intrahepatic activation of coagu-
lation would indeed drive elevated D-dimer and TAT levels in AD
and ACLF, one expects a relation between the extent of intrahepa-
tic fibrin deposition and levels of D-dimer and TAT, but againJHEP Reports 2019such analyses would require tissue biopsies. However, we found
that D-dimers were clearly increased in patients with organ fail-
ure, with the notable exception of liver failure. Indeed D-dimers
were not different between patients with high or low AD- or
ACLF-CLIF scores. These findings argue against substantial intra-
hepatic activation of coagulation but rather suggest that
elevated D-dimer levels are driven by extrahepatic activation of
coagulation, which could be related to extrahepatic organ injury.vol. 1 | 179–187 185
Table 4. Plasma level ofmarkers for activation of coagulation, oxidative stress and DNA in patients that survived beyond 30 days of admission and thosewho
did not.
Survived (n = 89) Died (n = 17) p
cfDNA, μg/ml 0.47 (0.36–0.65) 0.82 (0.70–1.31) <0.001
MPO-DNA complex, AU 0.86 (0.49–1.14) 0.99 (0.67– 1.28) n.s.
Nucleosome, mU 125 (51–302) 204 (132–403) n.s.
TAT, ug/ml 8.3 (4.1–16.3) 9.6 (7.1–20.6.) n.s.
D-dimers, ng/ml 2,962 (151–6,303) 6,310 (4,420–8,363) 0.01
IL-6, ng/ml 25.6 (11.6–74.7) 77.1 (41.7–137.0) 0.01
TBARS. μM 4.6 (3.7–8.1) 14.6 (6.8–16.2) <0.001
Shown are medians and interquartile ranges. Comparisons by Mann Whitney U test.
cfDNA, cell-free DNA; IL-6, interleukin 6; MPO, myeloperoxidase; TAT, thrombin-antithrombin complexes; TBARS, thiobarbituric acid-reactive substances.
Research ArticleWe do not have a clear explanation for why the injured liver
would not, but all other failing organs would contribute to coagu-
lation activation. Also, the fact that D-dimer, but not TAT levels
are related to organ injury and outcome suggest that the balance
between activation of coagulation and activation of fibrinolysis,
rather than activation of coagulation alone, is key in determining
intra-organ fibrin accumulation.
ACLF is characterized by high short-term mortality. These
patients have a narrow window for liver transplantation and the
supportive care may be futile and expensive.35 Distinguishing
between ACLF and traditional AD also requires biomarkers that
we currently lack, which means that the management strategy
is similar for patients with ACLF and those with traditional AD.
Differences in the intensity of systemic inflammation and organ
dysfunction between AD and ACLF may be exploited for this pur-
pose. Studies in critically ill patients without underlying liver dis-
ease have demonstrated that severe systemic inflammation may
lead to organ dysfunction and failure through direct cellular
injury, leading to the release of nuclear or mitochondrial DNA
that drive organ failure.36 Therefore, levels of circulating cfDNA
may be helpful predictors of outcome. Indeed, plasma levels of
cfDNA strongly predict intensive care unit mortality in patients
with severe sepsis.37,38 In line with these findings, in our cohort,
plasma levels of cfDNA were substantially higher in patients
who died within 30 days of admission. In addition, levels of IL-6
and TBARS were substantially higher in patients that died within
30 days. Collectively, these results suggest that inflammation
and oxidative stress with accompanying cellular death and
release of cfDNA, rather than neutrophil activation with NETosis
and NETosis-associated activation of coagulation and intra-organ
microthrombosis, drives development and/or progression of
ACLF. As plasma levels of cfDNA were higher in patients with all
types of organ failure (Table 3), it is likely that the cfDNA is not
only liver-derived, but is a result of cell death within all affected
organs. This conclusion is different from that of a previous study
in which the cell death markers caspase-cleaved keratin 18 and
keratin 18 were quantified in plasma from patients with AD and
ACLF.39 This study concluded that these cell death markers were
primarily of hepatic origin in patients with AD and ACLF.WhetherJHEP Reports 2019release of cfDNA is distinct from that of cleaved keratin 18 and
keratin 18, or whether the different conclusions between the stu-
dies are explained by patient characteristics would require addi-
tional study.
ACLF is a very heterogenous disease entity. Analyzing this het-
erogeneous group as a whole is a limitation of our study, which
was too small to allow for meaningful subgroup analyses. Future
larger studies should separately analyze patients based on under-
lying etiology and the severity of ACLF. Also, future studies should
take the precipitating event for decompensation into account.
Notably infection as a precipitating event must be studied sepa-
rately, given the role of NETs in infection and the inflammatory
component of ACLF.
The finding that NETosis does not appear to be an important
driver of outcome and that NETosis was not increased in patients
with AD/ACLF that developed sepsis, compared to those that did
not develop sepsis, challenges some of the recently outlined con-
cepts regarding the role of NETs in liver diseases,21 and the role
of NETs in driving organ failure in sepsis.40 Importantly, many of
these concepts were developed primarily using data from experi-
mental animal studies, which reinforces the need to validate such
concepts in human studies.
In the present study, blood samples were taken at a single
time point. Given the dynamic clinical course of acutely ill
patients with cirrhosis, and the fact that the clinical course of
these patients is a more accurate predictor of short-term out-
comes than the initial disease severity, this is a limitation of our
study. The analysis of serial samples would add valuable informa-
tion about the outcome of this patient population.
In conclusion, we found levels of circulating DNA, andmarkers
for inflammatory and oxidative stress to be elevated in patients
with AD and ACLF with a clear relation to development of organ
failure and short-term mortality. In addition, D-dimer levels
were related to organ failure and mortality, but not with severity
of liver disease. We have provided evidence that NETosis, inflam-
mation, and oxidative stress are not involved in activation of coa-
gulation in patients with AD and ACLF, which argues against a
role of NETosis in the progression of multiorgan failure in acutely
ill patients with cirrhosis.Financial support
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